Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indoximod with Pembrolizumab or Nivolumab in advanced melanoma
NCT03301636Phase 2Terminated
- Sponsor
- Lumos Pharma, Inc.
- Start
- Dec 2017
- Primary completion
- Oct 2019
- Countries
- 1
01
Overview
A Phase 2 trial of indoximod in melanoma, sponsored by Lumos Pharma, Inc.. Started Dec 2017; status: terminated.
02
Drugs
indoximod
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03301636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03301636.